ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a phase Ib/II open-label non-randomised clinical trial

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Protocol, Informed consent forms and SPIRIT checklist for the ACCEPT trial.

Related collections

Author and article information

Journal

Publisher: figshare

Publication date (Electronic): 2020

Publication date Created: 12 February 2020

Publication date Updated: 12 February 2020

Article

DOI: 10.6084/M9.FIGSHARE.11791275.V4

SO-VID: d36d872a-2c00-4bea-9a38-61b20764673d

License:

CC BY 4.0

History

Keywords: 119999 Medical and Health Sciences not elsewhere classified

Data availability:

Keywords: 119999 Medical and Health Sciences not elsewhere classified

Comments

Comment on this article

scite_

Cited by 1

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Authors: Andrew Davies, Sharon Barrans, Cathy Burton …

See all cited by

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a phase Ib/II open-label non-randomised clinical trial

Read this article at

International Journal of Management Studies

Journal

Article

History

Comment on this article